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Abstract: Leukemia associated antigens (LAAs) are being increasingly identiﬁ  ed by methods such as cytotoxic T-lymphocyte 
(CTL) cloning, serological analysis of recombinant cDNA expression libraries (SEREX) and mass spectrometry (MS). In 
additional, large scale screening techniques such as microarray, single nucleotide polymorphisms (SNPs), serial analysis of 
gene expression (SAGE) and 2-dimensional gel electrophoresis (2-DE) have expanded our understanding of the role that 
tumor antigens play in the biological processes which are perturbed in acute myeloid leukemia (AML). It has become 
increasingly apparent that these antigens play a dual role, not only as targets for immunotherapy, but also as biomarkers of 
disease state, stage, response to treatment and survival. We need biomarkers to enable the identiﬁ  cation of the patients who 
are most likely to beneﬁ  t from speciﬁ  c treatments (conventional and/or novel) and to help clinicians and scientists improve 
clinical end points and treatment design. Here we describe the LAAs identiﬁ  ed in AML, to date, which have already been 
shown to play a dual role as biomarkers of AML disease.  
Abbreviations: AML: acute myeloid leukemia; APL: acute promyelocytic leukemia; ATRA: all-trans-retinoic acid; B-CLL: 
B-cell chronic lymphocytic leukemia; CT: cancer-testis; CTL: cytotoxic T-lymphocyte; FAB: French-American-British; 
HI: hypusination inhibitors; HSP: heat shock protein; ITD: internal tandem duplication; LAA: leukemia associated antigen; 
MDS: myelodysplastic syndrome; MGEA6: meningioma antigen 6; MPD: myeloproliferative disease; MS: mass spectrom-
etry; NK: natural killer; PRAME: preferentially expressed antigen of melanoma; PRTN3: proteinase 3; RAGE-1: renal 
antigen 1; RHAMM: receptor for hyaluronic acid-mediated motility; RQ-PCR: real-time PCR; SAGE: serial analysis of 
gene expression; SCT: stem cell transplant; SEREX: serological analysis of recombinant cDNA expression libraries; SNPs: 
single nucleotide polymorphisms; UPD: uniparental disomy; WHO: World Health Organization; WT1: Wilm’s Tumor gene 1.
Keywords: Acute myeloid leukemia, leukemia/tumor-associated antigens, immunotherapy, cancer-testis antigens, SEREX, 
microarray, mass spectrometry.
Introduction
Acute myeloid leukemia (AML) describes a heterogeneous group of diseases which are typiﬁ  ed by the 
outgrowth of immature hematopoietic cells, known as blasts, in the bone-marrow and peripheral blood. 
Most patients with AML, who are younger than 60 years of age, achieve complete remission after 
polychemotherapy and/or stem cell transplantation (SCT) (Tallman et al. 2005). However, it is subse-
quent relapse with it’s high associated morbidity that leads to ﬁ  ve year survival rates of approximately 
50% (Lowenberg et al. 1999). It should be noted that the median age of AML patients is 63 years and 
for the majority of patients with AML, who are over 60 and ineligible for SCT, the rate of complete 
remissions are markedly reduced to 11% (Rowe et al. 2004). The karyotype provides the most important 
prognostic information in adult AML (Grimwade et al. 1998). Multivariate analysis revealed that an 
age above 70 was the other major negative prognostic factor for overall survival besides high-risk 
cytogenetics (Frohling et al. 2006). However, using conventional chromosome banding analysis, 
approximately 50% of AML patients lack chromosomal aberrations. For these AML patients, molecular 
genetic approaches become of major importance. The World Health Organization (WHO) classiﬁ  cation 
system (Vardiman et al. 2002) (overviewed in Figure 1) replaces the preceding French-American-British Biomarker Insights 2007: 2 70
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(FAB) classiﬁ  cation system and in addition to 
clinical data, also takes into consideration biolog-
ical characteristics, such as morphology, cytochem-
istry, immunophenotype, cytogenetics and molec-
ular biology. The separation of subgroups also 
allows the distinction of prognostic parameters 
and the identiﬁ  cation of patients who are better 
suited to speciﬁ  c treatment strategies.
Immunotherapy offers an opportunity to 
remove residual diseased cells in remission and 
can potentially reduce or eliminate the risk of 
relapse. During the last 20 years significant 
improvements have occurred in our ability to 
identify tumor antigens. Originally leukemia 
associated antigens (LAAs) were identiﬁ  ed by 
virtue of their role in leukemogenesis and were 
subsequently shown to be immunogenic. The 
serological analysis of recombinant cDNA 
expression libraries (SEREX) technique allowed 
the identiﬁ  cation of LAAs due to their recognition 
by humoral responses but also led to the demon-
stration that these antigens were recognized by 
CD4
+ and CD8
+ T cells as well as B-cells. More 
recently microarray, single nucleotide polymorphisms 
(SNPs) and 2-dimensional gel electrophoresis (2-DE) 
have allowed the large scale analysis of gene, RNA 
and protein differences between patient and 
normal donor samples. 
We have had a particular interest in identifying 
LAAs which may act as targets for the immuno-
therapy of AML. Tumor antigens such as Wilm’s 
tumor (WT1) (Menssen et al. 1995), preferentially 
expressed antigen of melanoma (PRAME) (Ikeda 
et al. 1997), proteinase 3 (PRTN3) (Molldrem 
et al. 1996) and the receptor for hyaluronic acid 
mediated motility (RHAMM/CD168) (Greiner et al. 
2002) have been used with some success in phase 
I/II clinical trials (Greiner et al. 2005; Guinn et al. 
2006b; Heslop et al. 2003; Li et al. 2006; Mailander 
et al. 2004; Oka et al. 2004) (reviewed elsewhere in 
Guinn et al. 2006b; Heslop et al. 2003). In addition, 
a growing group of LAAs have been shown to play 
a dual role as biomarkers in AML. In this review we 
describe some of these LAAs, whose capacity to act 
as biomarkers of disease stage, disease progression, 
relapse and survival have already been demon-
strated.
Associations between LAAs, 
Subgroups and Cytogenetics
Apart from acute promyelocytic leukemia (APL), 
none of the remaining subgroups of AML have a 
single cytogenetic aberration associated with all 
samples from that subtype (Figure 1). The 
PML-RARα oncogene is a chimeric protein 
produced by the t(15;17) translocation in APL and 
has been used as a target for DNA vaccinations in 
mice (Padua et al. 2003). This work clearly showed 
that a combination of conventional treatment (in 
this case all-trans-retinoic-acid) and immuno-
therapy could effectively improve survival rates 
in an animal model of APL. This work is now 
progressing into human clinical trials. Of note 
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Figure 1. Subclassiﬁ  cation of AML by the WHO system. Diagnosis of AML based on the World Health Organisation (WHO) classiﬁ  cation 
system (based on review by Vardimann et al. 2002) which superseded the French-American-British (FAB) classiﬁ  cation system.Biomarker Insights 2007: 2 71
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secondary cytogenetic changes occur in 32% (of 
161) APL patients examined and are associated 
with longer complete remission and event free 
survival (P = 0.03) in patients treated with chemo-
therapy (Slack et al. 1997). 
However, some genes are overexpressed in 
AML and are associated with speciﬁ  c subgroups 
of AML, such as PRAME. PRAME was ﬁ  rst iden-
tiﬁ  ed as an antigen in human melanoma by virtue 
of patient CTLs (Ikeda et al. 1997). PRAME is 
expressed in 45% of AML M2 and 75% of AML 
M3 patients (Matsushita et al. 2004) and PRAME 
positive patient samples have been shown to be 
susceptible to lysis by PRAME-speciﬁ  c CTLs 
(Morandi et al. 2006). 
Heat shock proteins (HSPs) may be referred to 
as molecular chaperones and are found in both 
normal and cancerous cells. These proteins are 
immunogenic, with the speciﬁ  city of the immune 
response being dictated by the peptides they chap-
erone (reviewed in Binder, 2006). Recent studies 
have investigated their frequency of expression 
and shown that HSP90 and 110 expression are 
associated with FAB M5 subtype and unfavorable 
and intermediate karyotypic groupings (Thomas 
et al. 2005).
WT1 is overexpressed in most types of human 
adult leukemia, and overexpressed in 90% of 
AML patients, except in AML FAB group M5, 
where expression occurs less frequently (Bergmann 
et al. 1997; Inoue et al. 1994; Miwa et al. 1992). A 
phase I clinical trial was recently described in which 
AML, MDS, breast and lung cancer patients were 
injected with either a naturally occurring or modi-
ﬁ  ed WT1 peptides. Twelve of 20 patients (who 
could be assessed) showed clinical responses and 
these could be clearly correlated with increased 
frequencies of the number of WT1 speciﬁ  c CTLs 
(Oka et al. 2004).
RAS is one of the most frequently occurring 
mutations in cancer and has been shown to play 
roles in the subversion of proliferation and differ-
entiation. RAS has also been shown to lead to 
enhanced apoptosis in preleukemic bone marrow 
(Darley et al. 1997) and conversely growth factor 
independence, leading to the avoidance of apop-
tosis in immortalized cells (Kinoshita et al. 1995). 
Peptide immunizations with a 13’mer peptide which 
represented patients own tumor ras led to ras-speciﬁ  c 
CD4
+ and/or CD8
+ responses. In addition, CD8
+ T 
cells speciﬁ  c for the Gly to Val mutation led to the 
killing of cells from a HLA-A2 matched tumor cell 
line carrying the corresponding mutation, but not 
those cells carrying wild type RAS (Khleif et al. 
1999). The NRAS mutation has been shown to be 
overrepresented in AML patients with the t(3;5) 
translocation and under represented in the t(15;17) 
subgroup (P < 0.001 for each) (Bowen et al. 2005). 
In the same study KRAS was shown to be over-
represented in the inv(16) group (P = 0.004) while 
RAS mutations and FLT3 ITD were rarely found 
to co-exist (P < 0.001). 
Bcl-2 is an anti-apoptotic protein which plays 
a pivotal role in preventing apoptotic cell death. 
Similarly it is thought that the targeting of cells 
which overexpress Bcl-2 has the potential to kill 
only those cancer cells with an associated growth 
advantage. Andersen et al.  (Andersen et al. 2005) 
demonstrated that patients with AML had sponta-
neously arising CTL-reactivity against Bcl-2 in 
patients but not normal donors, suggesting that 
vaccines against Bcl-2 could be effective against 
tumor cells which overexpress this protein.  Bcl-2 
overexpression has been shown to be associated 
with the M4 and M5 subtypes (p < 0.01) (Daneshbod 
et al. 2005). 
Telomerase reverse transcriptase (hTERT) is 
involved in telomere elongation and is frequently 
found to be expressed in human cancers and rarely 
in normal tissues. It has been the target of a number 
of immunotherapy clinical trials (reviewed in 
Carpenter and Vonderheide, 2006), due to it’s tumor 
associated expression. Monocyte derived dendritic 
cells from an AML cell line, were used to generate 
functional CTL clones with speciﬁ  city for hTERT 
(Santegoets et al. 2006). In addition to it’s expression 
in cancer and cancer stem cells, in AML hTERT 
levels have been found to be associated with CD34 
expression and chromosomal abnormalities 
(P = 0.01 and P = 0.001, respectively) (Xu et al. 
1998). Elevated hTERT levels have been associated 
with patients less likely to achieve complete remis-
sion (Zhang et al. 1996) and in patients with 
relapsed, rather than those newly diagnosed with 
AML (Huh et al. 2005; Tatematsu et al. 1996). 
Using microarray analysis on 195 AML patient 
samples at presentation Guinn et al. (Guinn et al. 
2006a) showed an association between the expres-
sion of the LAA, meningioma antigen 6 (MGEA6) 
(Heckel et al. 1997), and FAB subgroup. The renal 
antigen 1 (RAGE-1) (Gaugler et al. 1996) was also 
found to segregate with the less differentiated 
forms of AML as dictated by FAB subgroup but 
not by WHO subgroup, suggesting that both Biomarker Insights 2007: 2 72
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RAGE-1 and MGEA6 could be targeted, by immu-
notherapy, to the less differentiated forms of AML 
as indicated by FAB subtype.
Greiner et al. (Greiner et al. 2006) also exam-
ined a large dataset of 116 AML patient samples 
which had previously been analyzed by microarray. 
They showed an association between PRAME, 
PRTN3, LAMR1 and G250/CA9 and distinct 
karyotypes. Higher levels of PRAME expression 
was associated with t(8;21), del(7q)/–7 and t(15;17) 
while complex karyotypes and inv(16) were asso-
ciated with lower levels of PRAME expression. A 
higher relative level of PRTN3 was associated 
t(8;21) and inv(16) while t(9;11) and del(7q)/–7 
were associated with lower levels. Higher expres-
sion of LAMR1 and G250/CA9 was associated 
with del(7q)/–7, while G250/CA9 higher levels 
were associated with t(9;11). Complex karyotypes 
and t(15;17) were associated with lower relative 
levels of expression of G250. They also found WT1 
expression to be associated with the presence of 
FLT3 ITDs. 
Tumor Antigens as Biomarkers
of Survival
Bergmann et al. showed that high levels of WT1 
mRNA in AML were associated with poor long term 
outcome (Bergmann et al. 1997; Trka et al. 2002) 
while others have found no correlation (Gaiger 
et al. 1998; Greiner et al. 2006; Schmid et al. 1997; 
Yanada et al. 2004). This may be explained in part 
by the cut off for “high levels” of expression 
chosen by the authors, the methods of detection 
and the sample source. Quantitative assessment of 
WT1 transcripts using a nested reverse transcrip-
tion PCR titration assay indicated an association 
between the good and standard cytogenetic risk 
groups and poorer outcome in >90% of patients 
(Garg et al. 2003). The same study also showed a 
positive correlation between WT1 transcript levels 
and remission rates, disease free survival and 
overall survival (P = 0.003). Wt1 has been shown 
to regulate the expression of the proto-oncogene 
bcl-2, and expression of the two genes correlate 
signiﬁ  cantly (Karakas et al. 2002). In patients <60 
years of age, expression of BCL-2 and WT1 were 
associated with a reduced rate in continuing 
complete remission and increased death rate, in 
contrast to patients >60 years, where expression 
of these genes had no association with survival 
rates. Of note RAS mutations were not found to 
inﬂ  uence clinical outcome in terms of overall 
survival, disease free survival, complete remission 
or relapse rates (Bowen et al. 2005).  
In addition to it’s role as a marker of prognosis 
for AML patients (Kottaridis et al. 2001; Kottaridis 
et al. 2002) FLT3 has been used as a target for a 
humanized antibody (Li et al. 2004) which has 
been shown to have anti-FLT3 effects on leukemic 
cell lines in vitro and in xenograft models. Other 
groups have examined FLT3-ITD expression in 
AML and although it has been found to be associ-
ated with AML progression from MDS and a worse 
outcome in patients with AML in general (Pollard 
et al. 2006; Shih et al. 2004), this is still a matter 
for debate in APL. Gale et al. (Gale et al. 2005) 
examined FLT3 mutations in 203 PML-RARα 
positive APL and looked for associations between 
biological characteristics and response to targeted 
therapy. They found that patients with mutant FLT3 
had a higher rate of induction death (P = 0.04) but 
there was no signiﬁ  cant difference in relapse risk 
or overall survival at 5 years. Callens et al. (Callens 
et al. 2005) found that FLT3-ITD was associated 
with high white cell count, high Sanz index and 
M3 variant isoforms.  Although FLT3-ITD was 
associated with a trend towards poorer overall 
survival, RAS and FLT3-ITD mutations were not 
associated with complete remission, induction 
death or death in complete remission.
In 2002, Steinbach et al. (Steinbach et al. 2002) 
showed that the PRAME gene was expressed by 
CD34
+ stem cells which they suggested may 
constitute a problem for its targeting in tumor 
immunotherapy. They found overexpression of 
PRAME in 62% (n = 31) of childhood AML 
patients and that the rates of overall and disease-
free survival were higher in patients with elevated 
levels of expression. They also found that PRAME 
expression was signiﬁ  cantly higher in patients with 
t(8;21). Conversely, in adult AML Paydas 
et al. (Paydas et al. 2005) found that 30% of AML 
patient samples analyzed had PRAME expression 
(n = 74) and did not ﬁ  nd any correlation between 
PRAME expression and clinical characteristics, 
including response to therapy, progression-free and 
overall survival. PRAME was reported to have its 
highest level of expression in patients harboring 
the t(8;21) translocation and that unlike WT1, its 
expression levels correlated inversely with prog-
nosis (Steinbach et al. 2002).
 Bcl-2 is one of the antiapoptotic, and bax one 
of the proapoptotic genes, which regulate the mito-Biomarker Insights 2007: 2 73
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chondrial-mediated pathway of apoptosis (Oltvai 
et al. 1993). Bcl-2  has been shown to prolong the 
survival of leukemia cells (Mariano et al. 1992). 
Del Poeta et al. (Del Poeta et al. 2003) showed that 
an elevated bax/bcl-2 ratio was associated with a 
longer overall survival and disease free survival in 
patients (p = 00001 and p = 0.019, respectively) in 
a study of 225 de novo AML patients by ﬂ  ow 
cytometry.   Of particular interest bax/bcl-2 levels 
accurately predicted clinical response and outcome 
in patients with normal or unknown cytogenetics. 
In this group of patients (n = 147, 65% of the total 
patients analyzed) a higher bax/bcl-2 ratio was 
associated with a higher complete remission rate 
(p = 0.0016) and a longer overall survival. These 
data suggest that the measurement of the bcl-2:bax 
ratio in patient samples may be used as a sensitive 
indicator of clinical outcome. Previously Borg 
et al. (Borg et al. 1998) had shown that bcl-2 
expression was not related to survival while Ong 
et al. (Ong et al. 2000) had shown that high bax 
expression was a good prognostic indicator in 
AML, with patients exhibiting high bax expression 
at diagnosis having a signiﬁ  cantly better prognosis 
for disease-free, event-free and overall survival 
(p = 0.016). This suggests that it is in fact bax 
which is the prognostic indicator in the studies of 
bax/bcl-2 levels. However earlier studies indicated 
a poor prognostic association with high bcl-2 
expression in AML (Russell et al. 1995) and with 
shorter survival, complete remission and complete 
remission durations (Daneshbod et al. 2005), indi-
cating that either low bax and/or high bcl-2 levels 
give a worse prognostic indication. Survivin is a 
member of the inhibitor of apoptosis protein 
family, which by immunocytochemistry was never 
found in normal samples but was found in almost 
all AML patient samples examined (Invernizzi 
et al. 2004). Wagner et al. (Wagner et al. 2006) 
examined Survivin, the predominant transcript 
variant in AML, for it’s expression and that of the 
splice variants survivin-2B and survivin-∆Ex3 in 
74 adults with AML. They found that low expres-
sion of survivin-2B correlated with better overall 
survival and event free survival (p ≤ 0.01; 27 
months vs. 10 months) unlike Survivin and 
survivin-∆Ex3. 
In a study of 98 newly diagnosed AML patients, 
cytogenetics, CD34 positive expression, multidrug 
resistance positive expression and HSP110 positive 
expression were found to be major prognostic 
factors for overall survival (Thomas et al. 2005). 
The group found that despite treatment differences 
higher expression of all HSPs seemed to correlate 
with lower complete remission rates and shorter 
survival. In addition they found that expression of 
all HSPs were related to bcl-2 expression perhaps 
reﬂ  ecting the already established role of HSPs (such 
as HSP27, 60, 70 and 90) in apoptotic pathways.
By microarray analysis Guinn et al. (Guinn 
et al. 2006a) found no association between RAGE-
1 and/or MGEA6 expression (present or absent 
calls) and survival, however, MGEA6 expression 
was found to occur more frequently in patients who 
had cytogenetic abnormalities associated with poor 
versus standard versus good survival and the differ-
ence between each was statistically signiﬁ  cant 
(p < 0.0001, Chi2 pairwise analysis). Of note, no 
correlation was found between present and absent 
calls and patient survival when examining CA9, 
PRAME, RHAMM, RAGE-1 or MGEA6 expression 
individually or in combinations of CA9, PRAME 
and RHAMM or RAGE-1 and MGEA6 (Guinn 
et al. 2007). However when high or low MGEA6 
expression (as compared to the median level of 
expression) was examined in patients with present 
calls, a trend towards improved survival and 
elevated MGEA6 expression (p = 0.148) was 
found. 
Greiner et al. (Greiner et al. 2006) found a 
correlation between high G250/CA9 mRNA expres-
sion levels (as compared with the median in G250/
CA9 expressers) and a longer overall survival 
(p = 0.022). This trend was replicated with PRAME 
(p = 0.103) and a similar suggestion was found for 
RHAMM (p = 0.284). Of interest they showed that 
expression of at least one of the three TAAs, 
RHAMM/HMMR, PRAME or G250/CA9, provided 
the most favorable prognostic score (P = 0.005). 
They also found no correlation between PRTN3, 
WT1, TERT or LAMR1 and outcome, however 
elevated levels of BCL-2 suggested poorer overall 
survival although this was not statistically signiﬁ  cant 
(p = 0.250).
Rather than using the median as a cut off point 
above which G250/CA9, PRAME, RHAMM and 
MGEA6 expression were shown to be associated 
with improved prognosis (Greiner et al. 2006), 
there has been a recent suggestion that a group of 
“distinctly” high expressing AML patients could 
be identiﬁ  ed by real-time PCR (RQ-PCR) (Guinn 
et al. 2007). In the case of CA9/G250 and PRAME 
the existence of a group of patients (36% and 54%, 
respectively) with a 1 log higher expression than that Biomarker Insights 2007: 2 74
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of normal donors and the remaining AML patients 
were found. It was suggested that survival in this 
group of distinctly high expressers should be 
compared to normal donors and the remaining 
AML patients for future analyses of survival. 
Biomarkers for Minimal Residual 
Disease (MRD)
The analysis of MRD provides an indication of 
when molecular remission is achieved, through the 
RQ-PCR analysis of transcript levels from genes 
which are associated with disease load. However 
until recently AML has lacked good markers of 
MRD (reviewed in Raanani and Ben-Bassat, 2004). 
Data from studies using RQ-PCR protocols to 
monitor MRD in AML patients with t(8;21), 
inv(16) and t(15;17) transcripts (Krauter et al. 
1999; Marcucci et al. 2001; Martinelli et al. 2003; 
Miyamoto et al. 1995; Tobal et al. 2001; Tobal 
et al. 2000; Tobal and Yin, 1996; Viehmann et al. 
2003) support the capacity of RQ-PCR analysis to 
be used to detect very low transcript levels and 
their rise with ensuing relapse (reviewed in Guinn 
and Tobal, In press; Raanani and Ben-Bassat, 2004; 
Yin & Grimwade, 2002). However, to date, AML 
patients with identiﬁ  ed fusion genes represent 
approximately 55% of all AML cases and encom-
pass a vast list of aberrations. There is, therefore, 
a need to identify alternative gene targets that are 
either specifically expressed or significantly 
upregulated in leukemic cells in the majority of 
AML patients. The exception to this is PML-RARα  
in the AML M3 subgroup which provides an excel-
lent and very speciﬁ  c marker for MRD. Studies 
have shown that rigorous testing of PML-RARα 
transcripts and pre-emptive treatment at the point 
of molecular relapse can improve survival rates in 
a relatively small group of low risk patients 
(reviewed in Grimwade and Lo Coco, 2002).
We would expect that LAAs such as RHAMM, 
PRAME, and WT1 (reviewed in (Sugiyama, 1998) 
would provide better markers of MRD due to their 
frequent expression in AML patients samples as 
compared to cancer-testis (CT) antigens such as 
HAGE (Adams et al. 2002), BAGE (Greiner et al. 
2004), RAGE-1 (Guinn et al. 2005b), PASD1 
(Guinn et al. 2005a) and MAGE-A3 (Martinez 
et al. 2007) whose expression was, at most, found 
in 33% of AML patients at presentation. Although 
CT antigens show leukemia speciﬁ  c expression and 
are not detected in normal tissues, LAAs are often 
found to have elevated levels of expression in 
leukemia cells compared with equivalent normal 
donor cells. Greiner et al. (Greiner et al. 2004) 
reported the detection of high expression levels 
of a number of LAAs including MPP11, RHAMM, 
WT1, PRAME, G250, hTERT, and BAGE using 
RQ-PCR in AML patients. In addition they 
reported that RQ-PCR showed a tumor-speciﬁ  c 
expression of the antigens BAGE, G250 and 
hTERT, as well as highly tumor-restricted expres-
sion for RHAMM, PRAME and WT1. Antigens 
such as WT1 and PRAME have already been 
shown to play a predictive role in the monitoring 
of MRD (Greiner et al. 2006; Inoue et al. 1994; 
Matsushita et al. 2001).
WT1 has been shown to be a marker of 
MRD by several groups (Cilloni et al. 2002; 
Inoue et al. 1996; Osborne et al. 2005; Weisser 
et al. 2005) reviewed in (Sugiyama, 1998), with 
the suggestion that this would provide a tool for 
monitoring MRD in 70% of AML patients (Oster-
gaard et al. 2004). Cilloni et al. (Cilloni et al. 2002) 
showed that normal and regenerating bone marrow 
samples and purified CD34
+ cells expressed 
minimal amounts of the WT1 transcripts. They also 
showed that WT1 transcripts were frequently 
undetectable in normal peripheral blood. In contrast 
they found high levels of WT1 in the peripheral 
blood and bone marrow samples from acute 
leukemia patients at diagnosis and that the WT1 
transcript levels followed the pattern of other 
molecular markers, such as fusions transcripts, 
used in current MRD monitoring protocols. Most 
signiﬁ  cantly they and Barragan et al. (Barragan 
et al. 2004) found that increased WT1 transcript 
levels in the bone marrow and/or peripheral blood 
were predictive of impending relapse. Garg et al. 
(Garg et al. 2003)  were able to show that the 
monitoring of WT1 transcripts in AML patients by 
RQ-PCR could predict relapse in patients up to 6 
months before the onset of clinical relapse. The 
data showed that WT1 transcript levels at various 
phases of the disease (presentation, post induction, 
post consolidation chemotherapy) could add 
important prognostic information in distinguishing 
patients who have a poor prognosis from those who 
would respond well to chemotherapy and achieve 
long term remission (Garg et al. 2003). In slight 
contrast, Weisser et al. (Weisser et al. 2005) found 
that although WT1 levels correlated with a shorter 
overall survival and event free survival at days 
61–120 and 121–180, after the start of chemotherapy, Biomarker Insights 2007: 2 75
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they did not correlate with shorter overall survival 
and event free survival at diagnosis or between 
days 16–60. 
PRAME, which is expressed in 40% of adult 
AML patients (Tajeddine et al. 2006), has been 
shown to be a useful marker for MRD particularly 
where other tumor speciﬁ  c markers are unavailable 
(Matsushita et al. 2001; Matsushita et al. 2003). 
Tajeddine et al. (Tajeddine et al. 2006) found that 
PRAME expression closely correlated with AML1/
ETO levels in AML patients harboring the t(8;21) 
translocation. In addition they found that PRAME 
expression highly correlated with clinical data 
when sequentially following AML patients from 
onset to cytological remission or relapse.
Assays for Identifying New 
Biomarkers/LAAs
Many of the earliest LAAs were identiﬁ  ed as prod-
ucts of cytogenetic rearrangements and later 
targeted as disease speciﬁ  c antigens. Padua et al. 
(Padua et al. 2003) have described their work 
targeting PML-RARα in AML in mouse studies 
which are now progressing to clinical trials 
(reviewed in (Robin et al. 2005). Other ways in 
which LAAs have been identified, have been 
through the identiﬁ  cation of genes which play a role 
in leukemogenesis and were later shown to be targets 
for immunotherapy, through reverse or conventional 
immunology (reviewed in Guinn et al. 2006b).
We and others have used the SEREX technique 
(Sahin et al. 1995) to identify a large number of 
tumor antigens in presentation AML samples (Chen 
et al. 2005; Greiner et al. 2000; Greiner et al. 2003; 
Greiner et al. 2002; Guinn et al. 2005a). Some of 
these antigens had already been shown to play a 
role in the pathogenesis of solid tumors (such as 
NAB2, NY-BR-1 and ACVR2) or in leukemogen-
esis (including MYH11, RHAMM, MAPK10, 
BRAP and TRIP11). In addition these studies 
identified known leukemia antigens such as 
RHAMM, MAGE-A1 as well as novel targets for 
leukemia immunotherapy such as PASD1, SSX2IP 
and BAGE.
Microarray analysis of gene expression has 
provided a powerful tool to characterize the 
molecular mechanisms underlying many cancers. 
With regards to AML, cDNA microarray analysis 
has allowed the identiﬁ  cation of genes that are 
differentially expressed in leukemic blasts as 
compared to normal hematopoietic lineages, indi-
cate prognosis, show the gene expression effects 
of varying treatment regimes and identify the genes 
involved in the processes underlying disease 
(reviewed in Bullinger and Valk, 2005; Grimwade 
and Haferlach, 2004). cDNA microarray has been 
used to differentiate cytogenetic groups and to 
identify new subgroups within the intermediate 
risk group with a normal karyotype (Bullinger 
et al. 2004). More recently microarray was used 
to identify LAAs which were expressed in AML 
cells, but not equivalent normal donor cells 
(Guinn et al. 2005b), and Greiner et al. (Greiner 
et al. 2006) used microarray to show associations 
between G250/CA9, PRAME and RHAMM 
expression and survival.  In addition Chapiro et al. 
(Chapiro et al. 2006) used microarray to show that 
AML M3 has several features of a T-lymphoid cell 
changing our understanding of the molecular 
mechanisms underlying this unique subgroup of 
AML. The limitation of transcriptomics, is that 
transcript levels do not necessarily correlate with 
protein expression and it cannot detect important 
post-translational modifications. Balkhi et al. 
(Balkhi et al. 2006) recently showed that AML 
from various cytogenetic risk groups, healthy bone 
marrow and CD34
+ cells, could be distinguished 
based on protein expression and mass spectrometry 
(MS) peak patterns corresponding to post-transla-
tional modiﬁ  cation differences. 
2-DE has been used to analyse CD133
+ progen-
itor cell fractions from patients with various 
leukemic disorders. Ten potential biomarkers were 
identiﬁ  ed which included nuclear protein associ-
ated with mitotic apparatus (NuMA), heat shock 
proteins and redox regulators (Ota et al. 2003). In 
addition, Cui et al. (Cui et al. 2005) used 2-DE to 
proﬁ  le samples from acute leukemia patients and 
differentially expressed spots were identiﬁ  ed by 
MS. They found distinct protein proﬁ  les in FAB 
subtypes (M2, M3 and M5). Matrix-assisted laser 
desorption and ionization time-of-ﬂ  ight (MALDI-
TOF) MS and its derivative surface enhanced laser 
desorption and ionization (SELDI)-TOF MS are 
enabling technologies which have increased the 
sensitivity and throughput for the detection of 
novel leukemia antigens. MALDI-TOF MS has 
previously been applied to chronic myeloid 
leukemia (Knights et al. 2006) to identify processed 
and presented epitopes eluted from MHC which 
led to the identiﬁ  cation of a novel peptide from 
PRTN3, which was detected among the more 
abundant MHC-ligands. It can only be a matter of Biomarker Insights 2007: 2 76
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time before the same technology is used to identify 
epitopes in LAAs that are processed and presented 
on primary AML samples.
Future Directions
In the future it would be hoped that microarray 
could be used to personalize therapy, identify 
patients who will develop drug resistance, those 
who will respond well to novel therapies and those 
who are likely to survive conventional treatment. 
These studies demonstrate the potential of 2-DE 
and MS to molecularly characterize acute leukemia 
providing further insights into leukemogenesis, 
deﬁ  ning subgroups and promoting the identiﬁ  cation 
of new targets for speciﬁ  c treatment approaches. 
Proteomic techniques such as differential in-gel 
electrophoresis (DIGE), multidimensional 
protein-identiﬁ  cation technology (MudPIT) and 
ﬁ  eld effect transistor (FET)-based protein detec-
tion are being applied to the identiﬁ  cation of 
cellular and serum biomarkers (reviewed in 
Ludwig and Weinstein, 2005). Such studies are 
in their infancy but have the potential to identify 
proteins and post-translationally modiﬁ  ed forms 
of proteins associated with cancers, which may 
include some novel targets for immunotherapy. 
Down regulation of eukaryotic initiation factor 
5A has been recently described as a novel target for 
hypusination inhibitors (HI) and, furthermore, the 
combination of Imatinib and HI produced a syner-
gistic effect that was restricted to Imatinib resistant 
BCR-ABL
+ cells (Balabanov et al. 2006). The iden-
tiﬁ  cation of mechanistic markers for AML could 
also provide a new avenue to elucidate potential 
immunotherapeutic targets. BAFF and APRIL have 
been shown to be abnormally expressed on the 
membrane of B-cell chronic lymphocytic leukemia 
(B-CLL) blasts thereby conferring resistance to 
apoptosis (Kern et al. 2004). In fact, a soluble form 
of BAFF was also detected in patient sera but not 
in healthy donor controls.
SNPs analysis provides a rapid way in which 
regions of DNA within the genome with an 
abnormal gain or loss can be identiﬁ  ed, enabling 
the detection of oncogenes and/or tumor suppressor 
genes, respectively, which are involved in the 
pathogenesis of a particular disease. Fitzgibbon 
et al. (Fitzgibbon et al. 2005) used SNPs analysis 
to show that approximately 20% of AML patients 
exhibit large-scale cryptic regions of acquired 
homozygosity in the form of uniparental disomy 
(UPD). In 7 of 13 of these patients they found 
concurrent homozygous mutations at four distinct 
loci (WT1, FLT3, CEBPA and RUNX1). UPD has 
also been identiﬁ  ed as the cause for the cryptic 
chromosomal aberration for the inactivation of the 
NF1 gene, a tumor suppressor gene, in juvenile 
myelomonocytic leukemia (Stephens et al. 2006). 
MicroRNAs are a large family of highly conserved 
non-coding genes thought to be involved in 
temporal and tissue-speciﬁ  c gene regulation. Calin 
et al. (Calin et al. 2002) showed that in B-CLL, the 
microRNA cluster mir15a-mir16 was located in a 
region deleted or mutated in more than 68% of 
patients. These data suggest that SNPs and 
microRNAs have the potential to help elucidate 
important regulatory pathways in AML, which may 
help identify biomarkers of AML and targets for 
immunotherapy.
Concluding Remarks
We have described the expanding ﬁ  eld of AML 
antigen identiﬁ  cation and our increasing under-
standing of the role these gene products play in 
leukemogenesis. We detail the dual role that some 
of these LAAs play as biomarkers of prognosis, 
MRD and survival while a number of preceding 
reviews have described in detail the role of these 
antigens as potential targets for the immunotherapy 
of AML. It remains to be determined whether these 
antigens will be predictive of disease progression, 
response to treatment and whether they can play a 
similar role in predicting outcome to treatment in 
the same way that cytogenetic ﬁ  ndings do. Immu-
notherapies continue to be developed to target these 
LAAs as treatments for AML and our growing 
understanding of the role LAAs play in the patho-
genesis of leukemia can only aid in the develop-
ment of effective therapies.
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